Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TM30338 (obinepitide) Phase 2 weight loss study in obese subjects
2007-000993-22Phase 2Completed
- Sponsor
- 7TM Pharma
- Start
- Mar 2007
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity comparing TM30338 active treatment with Placebo control (2 arms). Primary endpoints: Change in body weight at 28 days and Safety and tolerability over 28 days. Started Mar 2007; status: completed.
02
Drugs
obinepitide
03
Conditions
obesity
Beyond the preview
Go deeper on 2007-000993-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000993-22.